Latest Research And Development News

EMVision Medical Devices’ latest Share Purchase Plan has attracted applications exceeding its initial $1 million target, with limited oversubscription capacity remaining ahead of the October 23 closing date.

Actinogen Medical has secured an initial $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending, bolstering funding for its Alzheimer’s and depression drug trials.

Metallium Limited announces a breakthrough rare earth recovery method using Flash Joule Heating with chlorination, promising faster, cleaner recycling of critical metals from magnet waste and advancing U.S. supply chain independence.

Telix Pharmaceuticals reports a robust 53% revenue jump in Q3 2025 and raises its full-year guidance, underpinned by key reimbursement wins and expanding clinical programs.

333D Ltd reports a fifth consecutive quarter of revenue growth, secures $1 million in fresh capital, and expands its blockchain healthcare initiatives while building a strategic Bitcoin treasury.

ReNerve Limited has achieved its first commercial sales of the EmpliQ™ amniotic tissue products, marking a significant step in its transition from R&D to commercialisation. The EmpliQ™ range complements its existing nerve repair solutions and targets a growing global wound care market.

ClearVue Technologies has raised A$4.6 million in a strongly supported placement to accelerate international certification and ongoing innovation of its solar façade products.

Orthocell Limited has reported a record $3 million quarterly revenue, driven by strong sales of its nerve repair product Remplir in Australia and Singapore, while advancing its rollout in the US and Canada ahead of schedule.

Assetora Limited has released its audited FY25 financial report showing a significant reduction in losses and a strengthened capital position, highlighted by the reopening of the DomaCom Fund and a $3 million private placement. The company aims to leverage these developments to accelerate growth in funds under management.

DroneShield is investing $13 million over three years to open a new counter-drone research facility in Adelaide, marking a key step in its global growth and technology development.

Stakk Limited has successfully raised $15 million through an oversubscribed equity placement, underscoring strong institutional confidence in its Embedded Finance growth strategy. The funds will accelerate expansion in the U.S. and Australian markets as the company’s recurring revenue surges.

LTR Pharma has increased its ownership in LevOmega to approximately 43% through a strategic A$1 million investment, reinforcing its commitment to sustainable, pharmaceutical-grade omega-3 development.